MASH is one of the fastest-growing causes of serious liver disease. Doctors know that excess fat, inflammation and scarring slowly damage the liver, but treating the condition remains difficult.
Many patients eventually develop cirrhosis or liver cancer, making the search for better therapies an urgent priority.
Scientists at Michigan Medicine have developed an experimental drug that may offer fresh hope. The research was published in The Journal of Clinical Investigation after the team tested the treatment in animal models. Rather than targeting the liver alone, the scientists focused on repairing the connection between the gut and the liver.
The digestive system contains trillions of bacteria that normally help with digestion and overall health. When this balance changes, harmful bacteria can multiply and produce chemicals that damage the body. The researchers found that one bacterium, Clostridium perfringens, produced large amounts of ammonia that weakened the protective lining of the intestines.
A healthy intestinal barrier acts like a filter, allowing nutrients to pass into the bloodstream while blocking harmful substances. When this barrier becomes damaged, bacterial products can leak into the blood and travel directly to the liver. This process increases inflammation and may speed up the progression of MASH.
The experimental medicine, called DT-109, was designed to break this harmful cycle. It lowered the levels of the bacteria producing excess ammonia and helped repair the intestinal barrier. By keeping harmful substances inside the gut instead of allowing them into the bloodstream, the drug reduced inflammation affecting the liver.
Researchers observed these improvements in both mice and non-human primates. The primate findings were especially important because their biology is closer to that of humans. The animals showed less liver inflammation and milder signs of fatty liver disease after treatment.
The study also suggested that DT-109 mainly works inside the digestive tract, although its benefits extend throughout the body. Earlier research has indicated that it may also help protect the heart by reducing artery plaque and calcium build-up in blood vessels. This raises the possibility that one treatment could benefit several diseases linked to poor metabolic health.
Before patients can receive the medicine, researchers must complete human clinical trials. These studies will examine the safest dose, possible side effects and whether the drug works as well in people as it does in animals. Until those trials are completed, DT-109 should still be considered an experimental treatment.
The work highlights how closely different organs in the body depend on each other. Instead of treating liver disease in isolation, scientists are beginning to recognise the important role of gut health in many chronic illnesses.
The study offers an exciting new direction for MASH research because it identifies a specific biological pathway that may be targeted with treatment.
Its combination of laboratory experiments and animal studies strengthens the findings, but more evidence is needed before it changes medical practice. Overall, the research provides strong scientific support for exploring gut-focused therapies as a future option for people living with fatty liver disease.
If you care about liver health, please read studies that refined fiber is link to liver cancer, and the best and worst foods for liver health.
For more health information, please see recent studies about how to boost your liver naturally, and simple ways to detox your liver.
Source: University of Michigan.
